3 days Ago By ABMN Staff
Vivos Therapeutics, Inc. ( NASDAQ:VVOS – Get Free Report ) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 56,900 shares, a decline of 34.
9% from the August 15th total of 87,400 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is currently 0.9 days.
Approximately 1.8% of the shares of the company are sold short. Institutional Trading of Vivos Therapeutics A hedge fund recently bought a new stake in Vivos Therapeutics stock.
Armistice Capital LLC purchased a new stake in Vivos Therapeutics, Inc. ( NASDAQ:VVOS – Free Report ) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 57,000 shares of the company’s stock, valued at approximately $709,000.
Armistice Capital LLC owned approximately 4.29% of Vivos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 26.
35% of the company’s stock. Vivos Therapeutics Stock Performance Shares of NASDAQ VVOS opened at $2.95 on Monday.
Vivos Therapeutics has a 1 year low of $1.91 and a 1 year high of $48.79.
The stock has a fifty day moving average price of $2.54 and a two-hundred day moving average price of $2.84.
The firm has a market cap of $9.52 million, a P/E ratio of -0.27 and a beta of 7.
74. Analyst Ratings Changes Separately, Ascendiant Capital Markets increased their price target on Vivos Therapeutics from $6.40 to $6.
60 and gave the stock a “buy” rating in a research note on Tuesday, August 20th. Check Out Our Latest Report on Vivos Therapeutics Vivos Therapeutics Company Profile ( Get Free Report ) Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
Further Reading Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
